



## Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Nov 10, 2025

### Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodium

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations, including one oral presentation, at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting® 2025, being held November 7 – 11, 2025 in Washington, D.C.

The oral and poster presentations highlighted the best-in-class potential of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection.

#### *Pevifoscorvir Sodium Post Treatment Data*

Newly presented data highlight outcomes for treatment-naïve or currently not treated HBeAg+ and HBeAg- subjects who completed 96 weeks of 300 mg pevifoscorvir sodium monotherapy, followed by 8 weeks of nucleos(t)ide analog (NA) monotherapy. Among HBeAg+ subjects, 8 of 10 subjects transitioned to NA monotherapy; of these, 6 (75%) maintained HBV DNA levels below the lower limit of quantification (LLOQ; 10 IU/mL, target detected [TD] or target not detected [TND]) throughout the NA only 8-week follow-up period. In the HBeAg- subjects, 8 of 9 subjects switched to NA monotherapy, and all 8 (100%) subjects maintained HBV DNA < LLOQ (10 IU/mL, TD or TND) throughout the NA only 8-week follow-up period. Reductions in HBV antigen and HBV RNA were also maintained during the NA-only 8-week follow-up period. Notably, these viral biomarkers, such as HBV antigens and HBV RNA, are typically unaffected by NA therapy, suggesting that pevifoscorvir sodium may reduce the cccDNA pool through engagement of its secondary mechanism of action.

Additionally, preclinical in vitro data demonstrated that ALG-001075, the active parent moiety of pevifoscorvir sodium, can prevent cccDNA formation and HBV DNA integration. This finding is further supported by cell-based studies presented at the meeting, which showed prevention of cccDNA establishment and HBV DNA integration following treatment with ALG-001075 (Poster #1251).

#### *96 Week Pevifoscorvir Sodium Monotherapy Data*

Additionally, the complete 96-week data from the Phase 1 monotherapy (NCT04536337) cohorts were presented showing the continued potential of pevifoscorvir sodium to become first-line therapy for chronic suppression.

In all 10 HBeAg+ subjects with very high mean baseline HBV DNA level of 8.0 log<sub>10</sub> IU/mL, a rapid, profound, and durable HBV DNA reduction was noted following daily oral dose of 300 mg pevifoscorvir sodium monotherapy. At Week 48, 6 of 10 subjects (60%) achieved HBV DNA < LLOQ (10 IU/mL, TD or TND). With treatment extension, this rate increased to 10 of 10 subjects (100%) at Week 96. Additionally, HBV DNA level declined below the undetectable level (< LLOQ (TND, ≤4.29 IU/mL)) in 5 of 10 (50%) subjects at Week 96.

In HBeAg- subjects receiving daily dose of 300 mg pevifoscorvir sodium monotherapy, all 11 (100%) had rapid decline in HBV DNA levels < LLOQ (TD or TND) by Week 24 with HBV DNA suppression maintained for up to 96 weeks of treatment; further decline in 8 of 9 (89%) subjects below the undetectable level of HBV DNA to < LLOQ (10 IU/mL, TND) was noted at Week 96.

Importantly, no viral breakthrough was observed in any subjects receiving pevifoscorvir sodium monotherapy for up to 96 weeks. Furthermore, concurrent multi-log<sub>10</sub> reductions in HBV antigens (HBsAg, HBeAg, and HBcrAg) in HBeAg+ subjects and HBcrAg decline in HBeAg- subjects were observed, suggesting the potential inhibition of cccDNA establishment by CAM-E secondary mechanism of action of pevifoscorvir sodium. A favorable tolerability profile was observed in both HBeAg+ and HBeAg- subjects receiving 300 mg pevifoscorvir sodium for up to 96 weeks.

"We are pleased to present these data at this year's The Liver Meeting, including our first oral presentation on pevifoscorvir sodium," said Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO of Aligos Therapeutics. "Our results continue to demonstrate the first-in-class and best-in-class potential of pevifoscorvir sodium, with post-treatment Phase 1 data suggesting a significant impact on the cccDNA reservoir in chronic HBV infection. The sustained responses observed after transitioning to standard-of-care therapy reinforce our belief that pevifoscorvir sodium affects the entire HBV lifecycle. We look forward to sharing further data as we advance the Phase 2 B-SUPREME study. Additionally, we are encouraged by the progress of our HBV ASO program, which has shown promising preclinical results for oligonucleotide treatment of HBV infection."

## *Preclinical Data*

The preclinical posters showcased Aligos' and its collaborators' continued innovation and commitment to advancing next-generation therapies in the liver and viral spaces with presentations spanning novel approaches and mechanistic insights.

Details of the presentations are as follows:

### **Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E under investigation for chronic hepatitis B virus (HBV) infection**

**Presentation #:** 0198

**Type:** Oral Presentation

**Title:** *Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not -treated Subjects with Chronic HBV*

**Presenter:** Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong

**Date/Time:** November 9, 2025 at 5:00pm – 6:30pm ET

**Session:** Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure

**Poster #:** 1208

**Type:** Poster Presentation

**Title:** *Sustained Reduction of HBV Antigen Levels During the 8-Week Follow-up Period in Treatment Naïve (TN) or Currently-Not-Treated (CNT) HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection After 96-Week 300 mg ALG-000184*

**Presenter:** Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong

**Date/Time:** November 7, 2025 at 8:00am – 5:00pm ET

**Session:** Hepatitis B ("1118-1367")

**Poster #:** 1251

**Type:** Poster Presentation

**Title:** *Capsid Assembly Modulator ALG-001075 Prevents cccDNA Formation and HBV DNA Integration In Vitro*

**Presenter:** Jordi Verheyen

**Date/Time:** November 7, 2025 at 8:00am – 5:00pm ET

**Session:** Hepatitis B ("1118-1367")

**Poster #:** 1338

**Type:** Poster Presentation

**Title:** *Capsid Assembly Modulator ALG-001075 Binds and Directly Targets HBeAg*

**Presenter:** Jordi Verheyen

**Date/Time:** November 7, 2025 at 8:00am – 5:00pm ET

**Session:** Hepatitis B ("1118-1367")

### **Preclinical**

**Poster #:** 1248

**Type:** Poster Presentation

**Title:** *Differentiation of HBV capsid assembly modulators based on stabilization of core protein oligomerization and residence time*

**Presenter:** Cheng Liu, PhD

**Date/Time:** November 7, 2025 at 8:00am – 5:00pm ET

**Session:** Hepatitis B ("1118-1367")

**Poster #:** 1330

**Type:** Poster Presentation

**Title:** *CAM-E and CAM-A Compounds Differentially Affect Phosphorylated and Non-Phosphorylated Hepatitis B Core Protein In Vitro*

**Presenter:** Rene Geissler, PhD, Abbott Diagnostics Division

**Date/Time:** November 7, 2025 at 8:00am – 5:00pm ET

**Session:** Hepatitis B ("1118-1367")

**Poster #:** 1155

**Type:** Poster Presentation

**Title:** *Lead Optimization and Selection of a Potential Best-in-Class HBV ASO*

**Presenter:** Jin Hong, PhD

**Date/Time:** November 7, 2025 at 8:00am – 5:00pm ET

**Session:** Hepatitis B ("1118-1367")

**Poster #:** 1103

**Type:** Poster Presentation

**Title:** *Two Pre-clinical Short Interfering RNA Molecules Targeting Human HSD17beta13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis*

**Presenter:** Jieun Song, PhD

**Date/Time:** November 7, 2025 at 8:00am – 5:00pm ET

**Session:** MASLD/MASH - Experimental: Basic ("1001-1117")

The presentations can be found on the Posters & Presentations section of the Aligos website ([www.aligos.com](http://www.aligos.com)) after the live event.

### **About Aligos**

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit [www.aligos.com](http://www.aligos.com) or follow us on LinkedIn or X.

### **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation, statements regarding Aligos' financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos' capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

### **Investor Contact**

Aligos Therapeutics, Inc.

Jordyn Tarazi

Vice President, Investor Relations & Corporate Communications

+1 (650) 910-0427

[jtarazi@aligos.com](mailto:jtarazi@aligos.com)

### **Media Contact**

Inizio Evoke

Jake Robison

Vice President

[Jake.Robison@inizioevoke.com](mailto:Jake.Robison@inizioevoke.com)